158 related articles for article (PubMed ID: 27055521)
1. Safety, tolerability, efficacy and pharmacodynamics of the selective JAK1 inhibitor GSK2586184 in patients with systemic lupus erythematosus.
Kahl L; Patel J; Layton M; Binks M; Hicks K; Leon G; Hachulla E; Machado D; Staumont-Sallé D; Dickson M; Condreay L; Schifano L; Zamuner S; van Vollenhoven RF;
Lupus; 2016 Nov; 25(13):1420-1430. PubMed ID: 27055521
[TBL] [Abstract][Full Text] [Related]
2. DRESS syndrome and reversible liver function abnormalities in patients with systemic lupus erythematosus treated with the highly selective JAK-1 inhibitor GSK2586184.
van Vollenhoven RF; Layton M; Kahl L; Schifano L; Hachulla E; Machado D; Staumont-Sallé D; Patel J;
Lupus; 2015 May; 24(6):648-9. PubMed ID: 25724932
[No Abstract] [Full Text] [Related]
3. Investigation of selective JAK1 inhibitor GSK2586184 for the treatment of psoriasis in a randomized placebo-controlled phase IIa study.
Ludbrook VJ; Hicks KJ; Hanrott KE; Patel JS; Binks MH; Wyres MR; Watson J; Wilson P; Simeoni M; Schifano LA; Reich K; Griffiths CE
Br J Dermatol; 2016 May; 174(5):985-95. PubMed ID: 26785220
[TBL] [Abstract][Full Text] [Related]
4. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial.
Wallace DJ; Furie RA; Tanaka Y; Kalunian KC; Mosca M; Petri MA; Dörner T; Cardiel MH; Bruce IN; Gomez E; Carmack T; DeLozier AM; Janes JM; Linnik MD; de Bono S; Silk ME; Hoffman RW
Lancet; 2018 Jul; 392(10143):222-231. PubMed ID: 30043749
[TBL] [Abstract][Full Text] [Related]
5. GSK2586184, a JAK1 selective inhibitor, in two patients with ulcerative colitis.
De Vries LCS; Ludbrook VJ; Hicks KJ; D'Haens GR
BMJ Case Rep; 2017 Aug; 2017():. PubMed ID: 28790099
[TBL] [Abstract][Full Text] [Related]
6. Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation study.
McBride JM; Jiang J; Abbas AR; Morimoto A; Li J; Maciuca R; Townsend M; Wallace DJ; Kennedy WP; Drappa J
Arthritis Rheum; 2012 Nov; 64(11):3666-76. PubMed ID: 22833362
[TBL] [Abstract][Full Text] [Related]
7. Safety and pharmacodynamics of venetoclax (ABT-199) in a randomized single and multiple ascending dose study in women with systemic lupus erythematosus.
Lu P; Fleischmann R; Curtis C; Ignatenko S; Clarke SH; Desai M; Wong SL; Grebe KM; Black K; Zeng J; Stolzenbach J; Medema JK
Lupus; 2018 Feb; 27(2):290-302. PubMed ID: 28691866
[TBL] [Abstract][Full Text] [Related]
8. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II).
Petri M; Bruce IN; Dörner T; Tanaka Y; Morand EF; Kalunian KC; Cardiel MH; Silk ME; Dickson CL; Meszaros G; Zhang L; Jia B; Zhao Y; McVeigh CJ; Mosca M
Lancet; 2023 Mar; 401(10381):1011-1019. PubMed ID: 36848919
[TBL] [Abstract][Full Text] [Related]
9. A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE).
Kalunian KC; Merrill JT; Maciuca R; McBride JM; Townsend MJ; Wei X; Davis JC; Kennedy WP
Ann Rheum Dis; 2016 Jan; 75(1):196-202. PubMed ID: 26038091
[TBL] [Abstract][Full Text] [Related]
10. Phase I, randomized, double-blind, placebo-controlled, multiple intravenous, dose-ascending study of sirukumab in cutaneous or systemic lupus erythematosus.
Szepietowski JC; Nilganuwong S; Wozniacka A; Kuhn A; Nyberg F; van Vollenhoven RF; Bengtsson AA; Reich A; de Vries DE; van Hartingsveldt B; Robinson DW; Gordon R; Hsu B
Arthritis Rheum; 2013 Oct; 65(10):2661-71. PubMed ID: 23896980
[TBL] [Abstract][Full Text] [Related]
11. Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study.
Merrill JT; Wallace DJ; Petri M; Kirou KA; Yao Y; White WI; Robbie G; Levin R; Berney SM; Chindalore V; Olsen N; Richman L; Le C; Jallal B; White B;
Ann Rheum Dis; 2011 Nov; 70(11):1905-13. PubMed ID: 21798883
[TBL] [Abstract][Full Text] [Related]
12. Repeated administration of dapirolizumab pegol in a randomised phase I study is well tolerated and accompanied by improvements in several composite measures of systemic lupus erythematosus disease activity and changes in whole blood transcriptomic profiles.
Chamberlain C; Colman PJ; Ranger AM; Burkly LC; Johnston GI; Otoul C; Stach C; Zamacona M; Dörner T; Urowitz M; Hiepe F
Ann Rheum Dis; 2017 Nov; 76(11):1837-1844. PubMed ID: 28780512
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics, tolerability, and preliminary efficacy of paquinimod (ABR-215757), a new quinoline-3-carboxamide derivative: studies in lupus-prone mice and a multicenter, randomized, double-blind, placebo-controlled, repeat-dose, dose-ranging study in patients with systemic lupus erythematosus.
Bengtsson AA; Sturfelt G; Lood C; Rönnblom L; van Vollenhoven RF; Axelsson B; Sparre B; Tuvesson H; Ohman MW; Leanderson T
Arthritis Rheum; 2012 May; 64(5):1579-88. PubMed ID: 22131101
[TBL] [Abstract][Full Text] [Related]
14. Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus.
Ginzler EM; Wallace DJ; Merrill JT; Furie RA; Stohl W; Chatham WW; Weinstein A; McKay JD; McCune WJ; Zhong ZJ; Freimuth WW; Petri MA;
J Rheumatol; 2014 Feb; 41(2):300-9. PubMed ID: 24187095
[TBL] [Abstract][Full Text] [Related]
15. A randomized, double-blind, placebo-controlled, dose-escalation study of the safety and efficacy of INCB039110, an oral janus kinase 1 inhibitor, in patients with stable, chronic plaque psoriasis.
Bissonnette R; Luchi M; Fidelus-Gort R; Jackson S; Zhang H; Flores R; Newton R; Scherle P; Yeleswaram S; Chen X; Menter A
J Dermatolog Treat; 2016 Aug; 27(4):332-8. PubMed ID: 26769332
[TBL] [Abstract][Full Text] [Related]
16. Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study.
Khamashta M; Merrill JT; Werth VP; Furie R; Kalunian K; Illei GG; Drappa J; Wang L; Greth W;
Ann Rheum Dis; 2016 Nov; 75(11):1909-1916. PubMed ID: 27009916
[TBL] [Abstract][Full Text] [Related]
17. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial.
Kalunian KC; Davis JC; Merrill JT; Totoritis MC; Wofsy D;
Arthritis Rheum; 2002 Dec; 46(12):3251-8. PubMed ID: 12483729
[TBL] [Abstract][Full Text] [Related]
18. Effect of raloxifene on disease activity and vascular biomarkers in patients with systemic lupus erythematosus: subgroup analysis of a double-blind randomized controlled trial.
Mok CC; Ying SK; Ma KM; Wong CK
Lupus; 2013 Dec; 22(14):1470-8. PubMed ID: 24113197
[TBL] [Abstract][Full Text] [Related]
19. Testosterone patches in the management of patients with mild/moderate systemic lupus erythematosus.
Gordon C; Wallace DJ; Shinada S; Kalunian KC; Forbess L; Braunstein GD; Weisman MH
Rheumatology (Oxford); 2008 Mar; 47(3):334-8. PubMed ID: 18238794
[TBL] [Abstract][Full Text] [Related]
20. Dehydroepiandrosterone treatment of women with mild-to-moderate systemic lupus erythematosus: a multicenter randomized, double-blind, placebo-controlled trial.
Chang DM; Lan JL; Lin HY; Luo SF
Arthritis Rheum; 2002 Nov; 46(11):2924-7. PubMed ID: 12428233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
